Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ligand Pharmaceuticals (LGND) Restructuring Costs (2016)

Ligand Pharmaceuticals' Restructuring Costs history spans 5 years, with the latest figure at $374000.0 for Q2 2016.

  • For Q2 2016, Restructuring Costs rose 71.56% year-over-year to $374000.0; the TTM value through Jun 2016 reached $1.2 million, up 1.01%, while the annual FY2016 figure was $1.0 million, 1.18% up from the prior year.
  • Restructuring Costs for Q2 2016 was $374000.0 at Ligand Pharmaceuticals, up from $244000.0 in the prior quarter.
  • Across five years, Restructuring Costs topped out at $562000.0 in Q4 2014 and bottomed at $43000.0 in Q2 2013.
  • The 5-year median for Restructuring Costs is $220500.0 (2015), against an average of $237687.5.
  • The largest annual shift saw Restructuring Costs soared 216.28% in 2014 before it crashed 58.36% in 2015.
  • A 5-year view of Restructuring Costs shows it stood at $357000.0 in 2012, then tumbled by 43.7% to $201000.0 in 2013, then surged by 179.6% to $562000.0 in 2014, then plummeted by 58.36% to $234000.0 in 2015, then skyrocketed by 59.83% to $374000.0 in 2016.
  • Per Business Quant, the three most recent readings for LGND's Restructuring Costs are $374000.0 (Q2 2016), $244000.0 (Q1 2016), and $234000.0 (Q4 2015).